Press release
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis Treatment Market: A Key Driver Powering Postmenopausal Osteoporosis Treatment Market Growth In 2025
Postmenopausal Osteoporosis Treatment
What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate?
The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected to rise from $10.1 billion in 2024 to $10.58 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.8%. Factors such as an aging population, the use of hormone replacement therapy, heightened awareness, reduction in fracture risk, and nutritional supplements are the reasons for this growth during the historic period.
The market size for postmenopausal osteoporosis treatment is anticipated to experience substantial growth in the following years. The market is predicted to surge to $13.44 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. The projected progress in the specified period could be due to the advancement in healthcare infrastructure, amplified screening programs, precision medicine methodologies, the use of biosimilars for osteoporosis treatment, women's health programs emphasizing bone health, integration of digital health, and regenerative medicine methods. Noteworthy trends that are expected to emerge during the forecast period comprise of diagnostic progressions, formulation of new drugs, emergence of new treatments, cooperative efforts towards drug development, and the integration of artificial intelligence.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12680
How Are Emerging Segments Shaping the Postmenopausal Osteoporosis Treatment Market Landscape?
The postmenopausal osteoporosis treatment market covered in this report is segmented -
1) By Drug Type: Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Bisphosphonates: Alendronate, Risedronate, Zoledronic Acid
2) By Vitamin D3: Cholecalciferol, Ergocalciferol
3) By Estrogen Agonist Or Antagonist: Selective Estrogen Receptor Modulators (SERMs), Tamoxifen
4) By Hormone Replacement Therapy: Estrogen Therapy, Combined Estrogen-Progestin Therapy
5) By Parathyroid Hormone Therapy: Teriparatide, Abaloparatide
6) By Other Drug Types: Calcitonin, RANK Ligand Inhibitors
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12680&type=smp
Which Growth Factors Are Influencing Postmenopausal Osteoporosis Treatment Market Expansion?
The expected growth of the postmenopausal osteoporosis treatment market can be attributed to the rising prevalence of osteoporosis. The medical condition, known for reducing bone mass and deteriorating bone tissue, increases the risk of fractures and weakens the bones. Postmenopausal osteoporosis treatment plays a crucial role in managing and preventing the disease. It also minimizes the chances of fractures, enhancing the quality of life and overall health for patients grappling with the condition. Citing data from Healthy Bones Australia, a non-government organization based in Australia, the number of fractures due to osteoporosis or osteopenia surged from 178,439 cases in 2021 to 183,105 cases in 2022 with a record in September 2022. Ergo, the escalating cases of osteoporosis are fueling the expansion of the postmenopausal osteoporosis treatment market.
Who Are the Dominant Players Across Different Postmenopausal Osteoporosis Treatment Market Segments?
Major companies operating in the postmenopausal osteoporosis treatment market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.
What Are the Latest Developing Trends in the Postmenopausal Osteoporosis Treatment Market?
The development of novel products is a significant trend emerging in the market for postmenopausal osteoporosis treatment. Leading companies in this sphere are concentrating on the creation of innovative products such as parathyroid hormone to enhance efficacy and ensure patient compliance. They are researching the potential of combined treatments and tailored medicine to improve results. Further, they are making long-term safety studies and patient assistance programs a priority to address any concerns and encourage adherence. The parathyroid hormone (PTH) is generated by the parathyroid glands, and it controls blood calcium levels. It accelerates the release of calcium from bones, bolsters reabsorption in the kidneys, and triggers vitamin D to heighten the absorption of calcium in the intestines. For instance, Apotex Corp., a pharmaceutical corporation based in Canada, introduced a teriparatide in November 2023. This recombinant parathyroid hormone significantly boosts bone mineral density and cuts down the risk of fracture in those suffering from osteoporosis. Owing to its anabolic effect that promotes bone formation, it is a crucial treatment for patients at high risk.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/postmenopausal-osteoporosis-treatment-global-market-report
Which Geographic Regions Are Expected to Dominate the Postmenopausal Osteoporosis Treatment Market in the Coming Years?
North America was the largest region in the postmenopausal osteoporosis treatment market in 2024. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Postmenopausal Osteoporosis Treatment Market?
2. What is the CAGR expected in the Postmenopausal Osteoporosis Treatment Market?
3. What Are the Key Innovations Transforming the Postmenopausal Osteoporosis Treatment Industry?
4. Which Region Is Leading the Postmenopausal Osteoporosis Treatment Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis Treatment Market: A Key Driver Powering Postmenopausal Osteoporosis Treatment Market Growth In 2025 here
News-ID: 4001825 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Postmenopausal
Postmenopausal Vaginal Atrophy (PVA) Market Massive Growth opportunity Ahead
Introduction
Postmenopausal Vaginal Atrophy (PVA), also referred to as genitourinary syndrome of menopause (GSM), is a chronic condition affecting women after menopause due to reduced estrogen levels. It is characterized by vaginal dryness, irritation, painful intercourse (dyspareunia), and urinary symptoms. Despite its high prevalence, PVA has historically been underdiagnosed and undertreated because of social stigma and lack of awareness.
In recent years, growing awareness of women's health, improved access to treatment options,…
Key Trends Reshaping the Postmenopausal Vaginal Atrophy Treatment Market: Advanc …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Postmenopausal Vaginal Atrophy Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for treating postmenopausal vaginal atrophy has seen significant growth recently. The market is projected to increase from $2.1 billion in 2024 to $2.28 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Postmenopausal Osteoporosis Market Size Unlocking New Opportunities for Success
The global postmenopausal osteoporosis market was valued at USD 9.7 billion in 2023 and is projected to reach USD 15.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.90% from 2024 to 2032.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-market
Postmenopausal Osteoporosis Market Overview:
The postmenopausal osteoporosis market is driven by the increasing prevalence of osteoporosis in postmenopausal women due to hormonal changes that reduce bone density.…
Postmenopausal Vaginal Atrophy - Drug Pipeline Landscape, 2022
Vaginal Atrophy is a condition in which vagina gets drier and thinner and inflammation of the Vaginal walls may occur when the body has less estrogen. Vaginal Atrophy in which Vaginal refers to the vagina while Atrophy means wasting away or diminution occurs most often after menopause. For Many women, Vaginal Atrophy not only makes intercourse painful but also leads to distressing urinary symptoms
Read more about Postmenopausal Vaginal Atrophy's pipeline,…
Postmenopausal Osteoporosis Market Share, Trends and Forecast to 2023
The postmenopausal osteoporosis market is expected to grow significantly during the forecast period (2018-2023). Osteoporosis is a skeletal disorder characterized by skeletal fragility, microarchitectural disruption, and low bone mass. It is a condition where the bone density and bone mass decreases and in the long run increases the risk of bone fracture. The global postmenopausal osteoporosis market is significantly growing due to some factors which include increasing geriatric population. Age…
Global Postmenopausal Osteoporosis Therapeutics Market
The Postmenopausal Osteoporosis Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related…
